Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

334.58
-3.9900-1.18%
Post-market: 334.50-0.0800-0.02%19:54 EDT
Volume:175.39K
Turnover:59.39M
Market Cap:9.32B
PE:-26.01
High:348.00
Open:340.00
Low:334.00
Close:338.57
52wk High:392.70
52wk Low:37.25
Shares:27.85M
Float Shares:24.08M
Volume Ratio:0.71
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.8634
EPS(LYR):-13.4758
ROE:-38.86%
ROA:-25.65%
PB:6.95
PE(LYR):-24.83

Loading ...

Praxis says elsunersen cuts seizures 77% in SCN2A DEE EMBRAVE Part A trial

Reuters
·
Apr 06

Praxis Precision Medicines Inc - Elsunersen Well-Tolerated With No Drug-Related Serious Adverse Events up to 8 Mg

THOMSON REUTERS
·
Apr 06

Praxis Precision Medicines Announces Positive Results From the Embrave Part a Trial of Elsunersen in Patients With Scn2a Early-Onset Developmental and Epileptic Encephalopathy

THOMSON REUTERS
·
Apr 06

How Investors May Respond To Praxis (PRAX) FDA Priority Review For Rare Pediatric Epilepsy Drug

Simply Wall St.
·
Apr 04

Praxis grants inducement RSUs covering 3,558 shares to 18 new employees

Reuters
·
Apr 03

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 03

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), PepGen Inc. (PEPG) and Omeros (OMER)

TIPRANKS
·
Apr 01

Jefferies Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

TIPRANKS
·
Mar 31

Analysts Offer Insights on Healthcare Companies: MannKind (MNKD) and Praxis Precision Medicines (PRAX)

TIPRANKS
·
Mar 31

Praxis Precision Medicines Secures US FDA Priority Review for Epilepsy Drug Application

MT Newswires Live
·
Mar 31

Praxis Precision announces FDA acceptance for priority review of relutrigine NDA

TIPRANKS
·
Mar 31

Praxis NDA for relutrigine wins FDA priority review, PDUFA date set for Sept. 27, 2026

Reuters
·
Mar 31

Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients With Scn2a and Scn8a Dees

THOMSON REUTERS
·
Mar 31

Praxis Precision Medicines Inc - Relutrigine Emerald Trial for Broad Dees Expected to Complete by End of 2026

THOMSON REUTERS
·
Mar 31

Praxis Precision Medicines Inc - FDA Assigns Pdufa Target Action Date of Sept 27, 2026 for Relutrigine

THOMSON REUTERS
·
Mar 31

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Biohaven Ltd. (BHVN) and Siemens Healthineers AG (OtherSEMHF)

TIPRANKS
·
Mar 11